In the interim results for the fiscal period ending March 2026, revenue reached 180.7 billion yen, net income was 15.7 billion yen, both increasing compared to the same period last year. Segments such as pharmaceuticals and imaging business performed well. Full-year forecasts have also been revised upward, maintaining stable performance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6134","jir_company_name":"Fujifilm Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/6134-20260514-03.pdf","jir_short_summary":"In the interim results for the fiscal period ending March 2026, revenue reached 180.7 billion yen, net income was 15.7 billion yen, both increasing compared to the same period last year. Segments such as pharmaceuticals and imaging business performed well. Full-year forecasts have also been revised upward, maintaining stable performance.","jir_summary":"### Performance Overview\nThe interim financial results for the fiscal period ending March 2026 achieved significant growth with revenue of 180.7 billion yen (YoY +16.8%) and net income of 15.7 billion yen (YoY +44.3%). The pharmaceuticals and imaging segments performed well, with particularly strong contributions from pharmaceutical sales expansion. Post-pandemic demand recovery and new product launches led to record-high profits. Full-year forecasts have been revised upward, supporting sustained solid performance.\n\n### Future Outlook and Investor Impact\nFull-year earnings are projected at revenue of 211.0 billion yen and net income of 33.0 billion yen, continuing to be robust. Expansion into new businesses and overseas markets are strengthening growth foundations. For investors, this indicates a stable profit base and growth potential, increasing long-term investment attractiveness. Shareholder return policies will include increased dividends, reflecting a focus on enhancing shareholder value.","jir_financial_highlights":"Revenue: 180.7 billion yen (YoY +16.8%)\nNet Income: 15.7 billion yen (YoY +44.3%)\nOperating Income: 29.2 billion yen (YoY +112.5%)","jir_category":"","jir_hashtags":"#Fujifilm, #FinancialResults, #JapaneseStocks","jir_key_figures":"Revenue: 180.7 billion yen (YoY +16.8%)\nNet Income: 15.7 billion yen (YoY +44.3%)\nOperating Income: 29.2 billion yen (YoY +112.5%)","jir_meta_title":"\u3010Fujifilm\u3011Financial Results for the Fiscal Period Ending March 2026 | Revenue 180.7 Billion Yen (+16.8%)","jir_meta_description":"Analysis of Fujifilm's interim financial results for fiscal year 2026. Revenue reached 180.7 billion yen, net income was 15.7 billion yen, with significant profit growth. Future performance outlook remains favorable.","jir_og_title":"Fujifilm 2026 Interim Financial Results | Revenue 180.7 Billion Yen, Profits Rise","jir_og_description":"Overview of Fujifilm's interim results for FY2026. Revenue reached 180.7 billion yen, net income was 15.7 billion yen, showing strong performance. Continued growth expected.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"March 2024\\\",\\\"March 2025\\\",\\\"March 2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Revenue (Billion Yen)\\\", \\\"data\\\": [161.2, 164.0, 180.7], \\\"borderColor\\\": \\\"#36A2EB\\\", \\\"fill\\\": false}]}\"}, {\"jir_chart_id\": \"net_profit\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"March 2024\\\",\\\"March 2025\\\",\\\"March 2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Net Income (Billion Yen)\\\", \\\"data\\\": [10.8, 10.9, 15.7], \\\"backgroundColor\\\": \\\"#FF6384\\\"}]}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Pharmaceuticals\\\", \\\"Imaging\\\", \\\"Others\\\"], \\\"datasets\\\": [{\\\"data\\\": [600, 700, 507], \\\"backgroundColor\\\": [\\\"#FF6384\\\", \\\"#36A2EB\\\", \\\"#FFCE56\\\"]}]}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Full-Year Forecast vs. Actual\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Revenue\\\", \\\"Net Income\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Forecast\\\", \\\"data\\\": [2110, 330], \\\"backgroundColor\\\": \\\"#4BC0C0\\\"}, {\\\"label\\\": \\\"Actual\\\", \\\"data\\\": [1807, 157], \\\"backgroundColor\\\": \\\"#FF6384\\\"}]}\"}]","ir_related_company":8080,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-51034","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n